Please login to the form below

insulin glargine

This page shows the latest insulin glargine news and features for those working in and with pharma, biotech and healthcare.

Sanofi poaches Peugeot's finance head

The group saw sales from its diabetes blockbuster Lantus (insulin glargine) plummet 18% to 911m (1.1bn) in the first quarter, quite a difference from the drug’s peak in 2014,

Latest news

FDA starts review of Sanofi’s oral type 1 diabetes drug

Sotagliflozin – which has the proposed trade name Zynquista – has been developed as an add-on therapy to insulin injections to help improve blood sugar control in type 1, early-onset diabetes, ... for big-selling basal insulin Lantus (insulin glargine
Sanofi’s latecomer PD-1 gets date for FDA verdict

blockbuster Lantus (insulin glargine) and a poor start for dengue vaccine Dengvaxia.
Sanofi warns of difficult few months as diabetes sales slump

As in earlier quarters, the main damage has come from diabetes blockbuster Lantus (insulin glargine), which saw sales decline 18% to 911m ($1.1bn) in the first quarter having reached a
Type 2 diabetes can be reversed in just four months, say researchers

calorie intake by 500 to 750 per day and continued use of glucose-controlling drugs (metformin, acarbose and in some cases basal insulin) to closely manage blood sugar levels. ... According to lead investigator Hertzel Gerstein, the team chose to use
Sanofi wins EU approval for new diabetes combination Suliqua

The dual-drug treatment combines the firm's blockbuster Lantus (insulin glargine) and with Lyxumia (lixisenatide) and aims to improve glycaemic control for those where metformin alone or in combination is ... same day as rival therapy Xultophy, Novo

More from news
Approximately 23 fully matching, plus 108 partially matching documents found.

Latest Intelligence

Mylan sees the UK paving the way for an insulin game changer

As biosimilars surge into the insulin market, governments are urged to seize ‘the opportunity of the century’. ... Mylan, the global healthcare company, has chosen the UK for the launch pad of its much-anticipated biosimilar version of the Sanofi
Going the distance

In fact, its last really big launch was some 14 years ago in the shape of Lantus (insulin glargine), the diabetes blockbuster that is now Sanofi's biggest-selling product. ... Following hot on the heels of Afrezza has been Toujeo (insulin glargine), the
Pharma deals during February 2013

Biosimilars continue to attract. Mylan's third Indian deal is in biosimilars, as it sets up an exclusive strategic collaboration with Biocon for three insulin biosimilars: Biocon's Glargine (the generic ... This deal together with the recent option

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

Sanofi promotes diabetes expert Paul Chew to chief medical officer

position. During his time at Sanofi, Dr Chew has been heavily involved in its growing diabetes business, holding responsibility for its long-acting insulin brand Lantus (insulin glargine), and his appointment